Durvalumab Conveys Benefit for All Biliary Tract Cancer Types

from Oncology Learning Network · host HMP Global

Ruth He, MD, discusses findings from a subgroup analysis assessing outcomes by primary tumor location in biliary tract cancer treated with durvalumab.

Episode metadata supplied by the publisher feed · Published Jul 22, 2022

Embed this episode

Attribution link and audio player

Ready to play

Durvalumab Conveys Benefit for All Biliary Tract Cancer Types

0:00 5:29

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Oncology Learning Network?

This episode is 5 minutes long.

When was this Oncology Learning Network episode published?

This episode was published on July 22, 2022.

Can I download this Oncology Learning Network episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!